van KleefMESpieringW. Hypertension: overly important but under-controlled. Eur J Prev Cardiol2017; 24: 36–43.
2.
SeegerJPBendaNMRiksenNPet al.Heart failure is associated with exaggerated endothelial ischemia–reperfusion injury and attenuated effect of ischemic preconditioning. Eur J Prev Cardiol2016; 23: 33–40.
3.
Saeid F, Aniseh J, Reza B, et al. Signaling mediators modulated by cardioprotective interventions in healthy and diabetic myocardium with ischaemia–reperfusion injury. Eur J Prev Cardiol 2018; 25: 1463–1481.
4.
VernonSTCoffeySBhindiRet al.Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. Eur J Prev Cardiol2017; 24: 1824–1830.
5.
ZafrirBAzencotMDobrecky-MeryIet al.Resting heart rate and measures of effort-related cardiac autonomic dysfunction predict cardiovascular events in asymptomatic type 2 diabetes. Eur J Prev Cardiol2016; 23: 1298–1306.
6.
Dalan1 R and Ling GL. The protean role of haptoglobin and haptoglobin genotypes on vascular complications in diabetes mellitus. Eur J Prev Cardiol 2018; 25: 1502–1519.
7.
WolkRBertoletMBrooksMMet al.Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D trial. Eur J Prev Cardiol2016; 23: 50–58.
8.
PokharelYSunWVillarealDTet al.Association between high-sensitivity troponin T and cardiovascular risk in individuals with and without metabolic syndrome: the ARIC study. Eur J Prev Cardiol2017; 24: 628–638.
9.
PiepoliMFHoesAWAgewallSet al.2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol2016; 23: NP1–NP96.
10.
LafeberMSpieringWVisserenFLet al.Impact of switching from different treatment regimens to a fixeddose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. Eur J Prev Cardiol2017; 24: 951–961.
11.
SelakVBullenCStepienSet al.Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease. Eur J Prev Cardiol2016; 23: 1393–1400.
12.
KotsevaKWoodDDe BacquerDet al.EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol2016; 23: 636–648.
13.
ToflerGHMassaroJLevyDAet al.Increased heart rate is associated with a prothrombotic state: the Framingham Heart Study. Eur J Prev Cardiol2017; 24: 382–388.
14.
AeschbacherSBossardMRuperti RepiladoFJet al.Healthy lifestyle and heart rate variability in young adults. Eur J Prev Cardiol2016; 23: 1037–1044.
15.
MandiniSGrazziGMazzoniGet al.A moderate 1-km treadmill walk predicts mortality in men with mid-range left ventricular dysfunction. Eur J Prev Cardiol2017; 15: 1670–1672.
